Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

MYBPC3 is the most frequently affected gene in hypertrophic cardiomyopathy (HCM), which is an autosomal-dominant cardiac disease caused by mutations in sarcomeric proteins. Bi-allelic truncating MYBPC3 mutations are associated with severe forms of neonatal cardiomyopathy. We reprogrammed skin fibroblasts from a HCM patient carrying a heterozygous MYBPC3 truncating mutation into human induced pluripotent stem cells (iPSC) and used CRISPR/Cas9 to generate bi-allelic MYBPC3 truncating mutation and isogenic control hiPSC lines. All lines expressed pluripotency markers, had normal karyotype and differentiated into endoderm, ectoderm and cardiomyocytes in vitro. This set of three lines provides a useful tool to study HCM pathomechanisms.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.scr.2021.102489DOI Listing

Publication Analysis

Top Keywords

mybpc3 truncating
12
bi-allelic mybpc3
8
isogenic control
8
hypertrophic cardiomyopathy
8
truncating mutation
8
mybpc3
5
generation bi-allelic
4
truncating
4
truncating mutant
4
mutant isogenic
4

Similar Publications

Background: No studies have explored the genetic differences between the Chinese and other ethnic hypertrophic cardiomyopathy (HCM) populations.

Methods: This cross-sectional study included Chinese patients ( = 593) with HCM and controls ( = 491) who underwent whole-exome sequencing. Rare variants in 16 validated HCM genes were assessed and compared with a United Kingdom HCM cohort ( = 1 232) and controls ( = 344 745).

View Article and Find Full Text PDF

Aims: Hypertrophic cardiomyopathy (HCM) is an inherited cardiomyopathy often caused by pathogenic variants in MYBPC3 and MYH7, encoding myosin-binding protein C3 and myosin heavy chain 7, respectively. These variants can cause increased actin-myosin crossbridge cycling, resulting in ventricular hypercontractility, but mice lacking Mybpc3 exhibited reduced left ventricular ejection time (LVET) as a sign of systolic dysfunction. In this study, we tested whether LVET is specifically altered in patients carrying MYBPC3 variants by retrospective echocardiographic analysis in two genotype-defined HCM cohorts.

View Article and Find Full Text PDF

Cardiac Phenotype Characterization at MRI in ALPK3 Associated Hypertrophic Cardiomyopathy.

J Cardiovasc Magn Reson

June 2025

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China; Cardiac Imaging and Target Therapy Lab, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China. Electronic address:

Background: Alpha-protein kinase 3 (ALPK3) was recently identified as a candidate gene associated with hypertrophic cardiomyopathy (HCM). However, clinical data regarding carriers of ALPK3 variants are limited.

Objectives: To evaluate the prevalence of heterozygous ALPK3 variants in adult patients with HCM through whole-exome sequencing, and to elucidate the phenotypes of individuals harboring these variants.

View Article and Find Full Text PDF

Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant disease caused by genetic variants in sarcomeric proteins, particularly in myosin binding protein C3 () and myosin heavy chain 7 (). Less known is that neonatal forms of HCM rapidly evolve into systolic heart failure and death within the first year of life. Although myosin inhibitors are now used to treat obstructive forms of adult HCM, there is still a need for novel therapeutic options and predictive animal models to assess them.

View Article and Find Full Text PDF

Genetic landscape of hypertrophic cardiomyopathy in Hong Kong Chinese population.

Front Genet

May 2025

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.

Introduction: Asian populations are underrepresented in the hypertrophic cardiomyopathy (HCM) genomic databases, which are currently largely dominated by Caucasian population. We aim to characterize the genetic landscape of HCM in patients from Hong Kong Chinese population.

Methods: From March 2023 to March 2024, fifty-three unrelated patients with an unequivocal clinical diagnosis of HCM were enrolled at a single tertiary center in Hong Kong and underwent genetic testing using a standardized 19-gene panel.

View Article and Find Full Text PDF